Clinical Trial

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Study acronym: iMMagine-3
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-09
notable Trial sites reduced: 124 -> 117 locations 2026-07-09
Trial Details
NCT Number NCT06413498
Lead Sponsor Kite, A Gilead Company
Collaborators: Arcellx, Inc.
Conditions Multiple Myeloma
Enrollment 452 participants
Start Date 2024-08-23
Primary Completion 2028-07 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-29